Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

First‐in‐human study with ACT‐539313, a novel selective orexin‐1 receptor antagonist
Priska Kaufmann, Marion Anliker‐Ort, Georg Golor, et al.
British Journal of Clinical Pharmacology (2020) Vol. 86, Iss. 7, pp. 1377-1386
Open Access | Times Cited: 23

Showing 23 citing articles:

Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
The Orexin/Hypocretin System, the Peptidergic Regulator of Vigilance, Orchestrates Adaptation to Stress
Miklós Jászberényi, Balázs Thurzó, Zsolt Bagosi, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 448-448
Open Access | Times Cited: 22
Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist
Angela Glen, Roland W. Bürli, David G. Livermore, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 100, pp. 129629-129629
Open Access | Times Cited: 8
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
Giacomo Salvadore, Pascal Bonaventure, Anantha Shekhar, et al.
Translational Psychiatry (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 40
Orexin Signaling: A Complex, Multifaceted Process
Natasha C. Dale, Daniël Hoyer, Laura H. Jacobson, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 26
A review of physiological functions of orexin: From instinctive responses to subjective cognition
LiBo Xia, Haiyan Liu, Bi Yan Wang, et al.
Medicine (2023) Vol. 102, Iss. 26, pp. e34206-e34206
Open Access | Times Cited: 14
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313
Priska Kaufmann, Marion Anliker‐Ort, Georg Golor, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 108, pp. 110166-110166
Closed Access | Times Cited: 24
Efficacy, safety, and tolerability of nivasorexant in adults with binge‐eating disorder: A randomized, Phase II proof of concept trial
Susan L. McElroy, Preciosa M. Coloma, Benjamin Berger, et al.
International Journal of Eating Disorders (2023) Vol. 56, Iss. 11, pp. 2120-2130
Open Access | Times Cited: 8
Evaluating the efficacy of the selective orexin 1 receptor antagonist nivasorexant in an animal model of binge‐eating disorder
Michel A. Steiner, Luca Botticelli, Giorgio Bergamini, et al.
International Journal of Eating Disorders (2024) Vol. 57, Iss. 7, pp. 1418-1432
Open Access | Times Cited: 2
Blockade of orexin receptor 1 attenuates morphine protracted abstinence-induced anxiety-like behaviors in male mice
Hongming Ye, Tong Cao, Qigang Shu, et al.
Psychoneuroendocrinology (2023) Vol. 151, pp. 106080-106080
Open Access | Times Cited: 5
Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity
Jazmine D. W. Yaeger, Kevin T. Krupp, Jason J. Gale, et al.
Medicine in Drug Discovery (2020) Vol. 8, pp. 100059-100059
Open Access | Times Cited: 14
Machine Learning Models to Predict Ligand Binding Affinity for the Orexin 1 Receptor
Vanessa Zhang, Shayna L. O’Connor, William J. Welsh, et al.
Artificial Intelligence Chemistry (2023) Vol. 2, Iss. 1, pp. 100040-100040
Open Access | Times Cited: 4
Impact of the Selective Orexin‐1 Receptor Antagonist ACT‐539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects
Benjamin Berger, Priska Kaufmann, Annelize Koch, et al.
The Journal of Clinical Pharmacology (2020) Vol. 60, Iss. 7, pp. 931-941
Closed Access | Times Cited: 10
Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects
Benjamin Berger, Priska Kaufmann, Matthias Berse, et al.
Pharmacology Research & Perspectives (2023) Vol. 11, Iss. 5
Open Access | Times Cited: 3
First‐in‐human study with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients
Marion Anliker‐Ort, Jasper Dingemanse, Chih‐hsuan Hsin, et al.
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 131, Iss. 2, pp. 114-128
Closed Access | Times Cited: 5
Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793
Cathy Préville, Pascal Bonaventure, Tatiana Koudriakova, et al.
ACS Medicinal Chemistry Letters (2020) Vol. 11, Iss. 10, pp. 2002-2009
Open Access | Times Cited: 7
Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers
Sander Brooks, Rob Zuiker, Cathy Bleys, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 6, pp. 577-589
Open Access | Times Cited: 1
Scalable, Chromatography‐Free Synthesis of 2‐(3‐Bromophenyl)‐2H‐1,2,3‐triazole through N−N Bond Forming Cyclization
Philipp Köhler, Ivan Schindelholz, Gabriel Schäfer
Helvetica Chimica Acta (2023) Vol. 106, Iss. 10
Closed Access | Times Cited: 1
Identification of Highly Selective Orexin 1 Receptor Antagonists Driven by Structure-Based Design
Uta Lessel, Marco Ferrara, N. Heine, et al.
Journal of Chemical Information and Modeling (2021) Vol. 61, Iss. 12, pp. 5893-5905
Closed Access | Times Cited: 3
Large‐Scale Synthesis of 4‐Methyl‐2‐(2H‐1,2,3‐triazol‐2‐yl)benzoic Acid – A Key Fragment of Single Orexin Receptor Antagonist ACT‐539313 – through Cu2O‐Catalyzed, Ligand‐Free Ullmann–Goldberg Coupling
Tony Fleischer, Gabriel Schäfer
Helvetica Chimica Acta (2022) Vol. 106, Iss. 1
Open Access | Times Cited: 2
Page 1

Scroll to top